In this review preliminary data on the follow-up of 141 babies born to mothers with antiphospholipid syndrome are reported. In spite of maternal treatment, the rate of both preterm delivery and low birth weight were 16 and 17%, respectively. At birth, no clinical evidence of perinatal thrombosis was observed. Placental transfer of antiphospholipid antibodies occurred in 20, 25 and 43% of cases for lupus anticoagulant, anticardiolipin and anti-b2-glycoprotein I antibodies, respectively. At 24 months of follow-up, four children showed behaviour abnormalities suggesting the possible need for long-term neurological evaluation in this clinical setting. Lupus (2012) 21, 761-763.
Introduction
The presence of antiphospholipid antibodies (aPL) in pregnant women is associated with a wide spectrum of adverse obstetric outcomes and neonatal complications. 1, 2 In 2003 we started a registry of children born to mothers with antiphospholipid syndrome (APS) with the aim to prospectively evaluate (1) the occurrence of gestational and neonatal complications, (2) the rate of aPL placental transfer and (3) the neuropsychological development of babies included in the registry. 3 
Design, patients and methods
The registry is a European, multicentre, prospective and longitudinal study which follows a cohort of babies born to mothers with APS. In this study, consecutive mothers presenting the clinical and laboratory features of APS, as defined by the Sapporo classification criteria, 4 were included. In addition, the detection of anti-b2-glycoprotein I antibodies (ab2GPI) was included in the laboratory criteria at the opening of the registry, even before their inclusion in the revised criteria published in 2006. 5 Data from both mothers and babies were collected from eight centres located in France, Italy and Slovenia. aPL including lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and ab2GPI (by Dilute Russell's Viper Venom Time [DRVVT] and enzyme-linked immunosorbent assay [ELISA] assays, respectively) were performed in mothers before and during pregnancy, and in infants at birth and during a follow-up period of 24 months. Specifically, aPL detection in infants was carried out according to aPL mother's positivity, therefore not all neonates were tested for all antibodies. The 99th percentile value, obtained from control sera of healthy adult donors, was used as level of cut-off for aCL and ab2GPI antibodies in both mothers and babies. The assessment of babies comprised clinical examination, growth data and neurodevelopment milestones, at 1-3, 9-12 and 18-24 months of life. In addition, in order to evaluate the turnover of passively acquired aPL, results obtained in a subgroup of 30 babies Correspondence to: Dr Mario Motta, Neonatology and Neonatal Intensive Care, Children's Hospital of Brescia, Pzz. le Spedali Civili -25123 Brescia, Italy Email: mario.motta@spedalicivili.brescia.it born to aPL-positive mothers with autoimmune diseases and followed in Brescia were compared with age-matched control infants. In particular, in these two groups of infants, reactivity against IgG ab2GPI was detected at birth and at 12 months of follow-up by an ELISA. 6 The study was conducted according to the Helsinki declaration and was approved by the Institutional Review Boards of both the University of Brescia and the Spedali Civili's Hospital of Brescia, Italy. Written informed consent from parents of neonates was obtained at birth.
Preliminary results
In a period of 6 years, from 2003 to 2009, 138 mothers and 141 children (three twin pregnancies) were included in the registry. One hundred and eight women had a diagnosis of primary APS and 30 of secondary APS. Among secondary APS, 18 mothers suffered from systemic lupus erythematosus (SLE) and 12 from other miscellaneous autoimmune diseases. A purely obstetrical APS were observed in 89 mothers, whereas thrombotic and mixed (obstetrical and thrombotic) APS were found in 35 and 14 mothers, respectively. During pregnancy the 89 cases of primary APS were treated with low-dose aspirin combined with low-molecular-weight heparin, whereas 25 and 15 cases of secondary APS were treated with corticosteroids and hydroxychloroquine, respectively, in combination with aspirin and heparin.
Twenty-three out of 141 (16.3%) neonates were born at less than 37 weeks of gestation; of these, four (2.8%) were born at less than 33 weeks of gestation. Twenty-four out of 141 (17%) neonates had low birth weight (body weight less than 2500 g) and two (1.4%) of these had very low birth weight (less than 1500 g). Moreover, 16/141 (11.3%) neonates were small for gestational age. No clinical evidence of perinatal thrombosis was observed in any cases. At birth, IgG aPL were detected in 43/ 127 (34%) investigated neonates. In particular, LA, aCL and ab2GPI were observed in 9/45 (20%), 25/ 99 (25%) and 26/60 (43%) newborns of aPL-positive mothers, respectively. Among the 43 aPL-positive neonates, 29 neonates had a single aPLpositivity, 11 had a double aPL-positivity and 3 a triple aPL-positivity.
Forty-six children were subsequently retested for aPL at 3 and 9 months of life and 27 children at 24 months. aPL findings at follow-up are summarized in Table 1 . Thirteen aPL-positive children at follow-up, 5 and 8 positive cases for IgG aCL and IgG ab2GPI, respectively, were negative at birth.
In the subgroup of 30 babies born to aPL-positive mothers with autoimmune diseases, the median titer of IgG ab2GPI detected at birth was significantly higher from that obtained in age-matched controls: 0.197 OD (interquartile range 0.101-0.435 OD) versus 0.032 OD (interquartile range 0.023-0.047 OD), p < 0.001 by Mann-Whitney U-test. In contrast, at 12 months follow-up the median titer of IgG ab2GPI was similar in the two groups: 0.235 OD (interquartile range 0.064-0.317 OD) versus 0.147 OD (interquartile range 0.052-0.431 OD), p < 0.84 by Mann-Whitney U-test.
Out of 42 children who were followed-up to 24 months of life, 4 children showed behavioural abnormalities including 1 case of autism, 2 cases of learning disabilities and 1 case of psychomotor delay associated with axial hypertonia. These four children were born at term of gestation to mothers with a diagnosis of primary obstetrical APS and treated during pregnancy with low-dose aspirin and heparin. One of them was from a bichorial twin pregnancy with intrauterine growth restriction and another was positive at birth for IgG aCL.
Discussion
Preliminary results from this multicentre prospective study show that, in spite of treatment, some complications related to maternal APS, such as preterm delivery and intrauterine growth restriction, are still present and more frequent than in the general population. The absence of clinically evident thrombotic events in this cohort of infants suggests a negligible risk of thrombosis secondary to maternal, passively acquired, aPL. In addition, since the aPL cut-off values are significantly lower in the newborns rather than in the adults, the placental transference of aPL might be underestimated if cut-off extrapolated from adults are utilized. 7 The relevant percentage of aPL positivity during early childhood, in particular observed for ab2GPI reactivity in both children born to mothers with aPL-positive autoimmune disease and in agematched controls, supports the hypothesis of a de novo synthesis of 'innocent' auto-antibodies that do not cause thrombotic events in this clinical setting. 8, 9 Moreover, we can speculate that during infancy the generation of these new auto-antibodies may be induced to the exposure to adjuvants or to other environmental agents such as infectious diseases. 10 Finally, preliminary observations of some cases of abnormal behavior development suggests to perform a long-term neurological assessment of these babies.
